Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 25;1:790456. doi: 10.3389/fradi.2021.790456

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Gaudino, Marziali, Giordano, Gigli, Varcasia, Magnani, Chiesa, Balducci, Costantini, Della Pepa, Olivi, Russo and Colosimo.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Pattern A. MRI changes in recurrent high grade glioma under regorafenib, pattern A. MRI scans performed at baseline (top image) and 3 months after first administration of REG therapy (bottom image). T2-weighted images (a,a'), T1-weighted images with gadolinium (b,b'), DWI images (c,c'), apparent diffusion coefficient (d,d'), and SWI images (e,e') are shown from left to right. The 3-month follow-up showed increase in size, more than 25%, of enhancing tumor in the left temporo-mesial area, and progressive extension into the ipsilateral parahippocampal gyrus. T2 signal intensity was similar to the previous MR exam, but contained focal hyperintensities on DWI (corresponding to low ADC values), and multiple black dots on SWI.